Citations

Clear

6 citation(s) found for "Sharma, Rahul".

Glomerular-Targeted Delivery of Low-Dose Prednisolone Attenuates Established Lupus Nephritis in MRL/lpr Mice
Williams, Kristof , Agyekum, Georgina , Patne, Akshata, Markoutsa, Eleni, Chellappan, David Raj, Hall, Nathan, Tian, Zhi , Soto, Nohely Hernandez, Cuadrao, Sebastian, Lozonschi, Isabella, Fu, Liying, Haight, Lilliana, Sharma, Rahul, Mohapatra, Subhra, Wang, Lei, Liu, Ruisheng, Fu, Liying, Sharma, Rahul, Wang, Lei , Mohapatra, Shyam S. , Liu, Ruisheng

Mayo Clinic

No container title available | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.01.742194 Get It

Abstract Background Lupus nephritis remains a major cause of chronic kidney disease and kidney failure in systemic lupus erythematosus. Glucocorticoids are central to treatment but are limited by systemic toxicity. We evaluated whether a previously characterized collagen IV α3-targeted liposomal nanoparticle formulation carrying low-dose prednisolone could attenuate established lupus nephritis in MRL/lpr mice. Methods Female MRL/lpr mice with disease present at treatment initiation and C57BL/6J control mice received saline or collagen IV α3-targeted prednisolone-loaded nanoparticles (Col4-α3-Pred-NPs). Renal outcomes were assessed by longitudinal proteinuria, glomerular filtration rate (GFR), survival, kidney histopathology, renal IgG and C3d deposition, dUTP/TUNEL-associated injury staining, and renal cytokine/chemokine profiling. Body weight, food and water intake, and blood glucose were monitored as measures of general condition and preliminary tolerability. Results Col4-α3-Pred-NPs improved survival in MRL/lpr mice, reduced cumulative proteinuria burden, and attenuated terminal GFR decline compared with saline-treated MRL/lpr controls. Treatment reduced glomerular and tubulointerstitial injury, lowered composite EGTI histopathology scores, decreased terminal kidney enlargement, reduced glomerular IgG deposition and renal dUTP-positive injury signals, and reduced renal signals for IL-28A/B, IL-7, PD-ECGF, IL-11, CCL6/C10, and IL-15. C3d deposition was not significantly altered. Nanoparticle treatment was not associated with sustained treatment-related increases in blood glucose or body-weight loss during the measured study period. Conclusions Collagen IV α3-targeted liposomal delivery of low-dose prednisolone attenuated established lupus nephritis in MRL/lpr mice and improved renal structural, functional, inflammatory, and survival outcomes. These findings support further evaluation of glomerulus-targeted nanotherapy as a potential strategy to improve the precision and therapeutic index of glucocorticoid treatment in lupus nephritis.
Glomerulus-targeted nanotherapy via collagen IV-α3 binding enhances renal immunoregulation in lupus nephritis
Wang, Lei , Markoutsa, Eleni, Venkatadri, Rajkumar , Sharma, Rahul, Esquivel, Carlos, Patne, Akshata, Wei, Jin, Zhang, Jie, Williams, Kristof , Lawless, William, Muskan, Amtul, Fu, Liying, Mayilsamy, Karthick, Mohapatra, Subhra, Mohapatra, Shyam, Liu, Ruisheng, Sharma, Rahul, Esquivel, Carlos O. , Mayilsamy, Karthick , Mohapatra, Shyam, Liu, Ruisheng

Mayo Clinic

Clinical Science | August 5, 2026 | Volume: 140 | Issue: 9 | Pages: 1895-1913

10.1042/cs20261409 | PMID 42554713 Get It

Abstract Lupus nephritis (LN) requires long-term immunosuppressive therapy, which is often associated with severe systemic side effects. Therefore, new therapeutic strategies that maintain high efficacy while minimizing adverse effects are essential. Although nanomedicine has advanced systemic and kidney-targeted drug delivery, a reliable method for glomerulus-specific delivery is lacking. Collagen IV (Col4)-alpha 3, located in the glomerular basement membrane at the blood–tissue interface through fenestrated capillary endothelium, represents an ideal target for glomeruli delivery. Herein, we developed a novel liposomal nanoparticle conjugated with a Col4-alpha 3-binding peptide (Col4-α3-NPs) for selective glomerular targeting. Prednisolone-loaded Col4-α3-NPs were administered to lupus-prone mice twice weekly for 8 weeks. Kidney injury and function were evaluated biweekly, and renal immune cell populations were analyzed by flow cytometry at study completion. The results show that rhodamine-labeled NPs predominantly accumulate in kidney glomeruli 48 h after intravenous injection. The Col4-NP system demonstrated stable and prolonged release of the encapsulated drug for over 48 h. Lupus-prone mice treated with prednisolone-loaded Col4-NPs showed significantly improved renal function and histology, including a 30% increase in glomerular filtration rate, a 56% reduction in proteinuria, and decreased IgG deposition and fibrosis. Notably, treatment also enhanced renal regulatory T cell populations. These findings suggest that glomerulus-targeted Col4-α3-NPs hold significant translational promise. This platform may offer an effective, site-specific treatment for LN while minimizing systemic side effects and could be adapted for other glomerular diseases requiring targeted therapy.
Glomerulus-Targeted Nanotherapy via Collagen IV-α3 Binding Enhances Renal Immunoregulation in Lupus Nephritis
Wang, L Q, Markoutsa, Eleni, Venkatadri, Rajkumar , Sharma, Rahul, Esquivel, Carlos, Patne, Akshata, Wei, Jin, Zhang, J, Williams, Kristof , Lawless, William, Muskan, Amtul, Fu, Liying, Mayilsamy, Karthick, Ss, Mohapatra, Mohapatra, Shyam, Wang, Lei , Esquivel, Carlos O. , Zhang, Jie, Fu, Liying, Mayilsamy, Karthick , Mohapatra, Subhra, Mohapatra, Shyam, Liu, Ruisheng

Mayo Clinic

No container title available | July 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.14.738533 | PMID 42538937 Get It

ABSTRACT Lupus nephritis requires long-term immunosuppressive therapy, which is often associated with severe systemic side effects. Therefore, new therapeutic strategies that maintain high efficacy while minimizing adverse effects is essential. Although nanomedicine has advanced systemic and kidney-targeted drug delivery, a reliable method for glomerulus-specific delivery is lacking. Collagen IV (Col4)-alpha 3, located in the glomerular basement membrane (GBM) at the blood–tissue interface through fenestrated capillary endothelium, represents an ideal target for glomeruli delivery. Herein, we developed a novel liposomal nanoparticle conjugated with a Col4-alpha 3 binding peptide (Col4-α3-NPs) for selective glomerular targeting. Prednisolone-loaded Col4-α3-NPs were administered to lupus-prone mice twice weekly for 8 weeks. Kidney injury and function were evaluated biweekly, and renal immune cell populations were analyzed by flow cytometry at study completion. The results show that rhodamine-labeled NPs predominantly accumulate in kidney glomeruli 48 hours after intravenous injection. The Col4-NP system demonstrated stable and prolonged release of the encapsulated drug for over 48 hours. Lupus-prone mice treated with prednisolone-loaded Col4-NPs showed significantly improved renal function and histology, including a 30% increase in glomerular filtration rate (GFR), a 56% reduction in proteinuria, and decreased IgG deposition and fibrosis. Notably, treatment also enhanced renal regulatory T cell (Treg) populations. These findings suggest that glomerulus-targeted Col4-α3-NPs hold significant translational promise. This platform may offer an effective, site-specific treatment for lupus nephritis while minimizing systemic side effects and could be adapted for other glomerular diseases requiring targeted therapy.
Real-World Outcomes of Transcatheter Tricuspid Valve Replacement
Makkar, R R, Gupta, A, O’Neill, Brian P., Lalani, Christina , Sharma, Rahul P., Yadav, Pradeep, Frisoli, Tiberio M., Thourani, Vinod, Eleid, Mackram F., Lee, James, Babaliaros, Vasilis C., Haeffele, Christiane , Bajwa, Tanvir , Flueckiger, Peter, Cubeddu, Robert J., Davidson, Laura J., Padang, Ratnasari , Spinetto, Pedro Villablanca, Narang, Akhil , Williams, Mathew, Gleason, Patrick, Tang, Gilbert H. L., Khera, Sahil , Vavalle, John P., Byku, Isida , Depta, Jeremiah P., Garcia, Santiago, Kapadia, Samir, Zajarías, Alan , Chanin, Jake, Kodali, Susheel K., Herrmann, Howard C., Morse, M. Andrew, Petrossian, George , Sivak, Joseph A. , Hahn, Rebecca T., Song, Yang, Leon, M.B., Yeh, Robert W., Davidson, C, Haeffele, Christiane , Makkar, Raj , Gupta, Aakriti , O’Neill, Brian Patrick , Sharma, Rahul P., Yadav, Pradeep , Frisoli, Tiberio , Thourani, Vinod H. , Makar, Moody M. , Eleid, Mackram F. , Lee, James, Babaliaros, Vasilis , Flueckiger, Peter B. , Davidson, Laura J., Allaqaband, Suhail Q. , Williams, Mathew R., Gleason, Patrick T. , Tang, Gilbert H.L. , Vavalle, John P. , Depta, Jeremiah P , Garcia, Santiago A. , Kapadia, Samir , Kodali, Susheel , Herrmann, Howard C. , Morse, M. Andrew M. , Hahn, Rebecca T , Song, Yang, Yeh, Robert W. , Davidson, Charles J.

Mayo Clinic

JAMA | April 13, 2026 | Volume: 335 | Issue: 18 | Pages: 1606

10.1001/jama.2026.3446 | PMID 41973411 Get It

Importance Transcatheter tricuspid valve replacement (TTVR) demonstrated superior outcomes over medical therapy in patients with severe tricuspid regurgitation (TR) in the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device II (TRISCEND II) randomized clinical trial, and received regulatory approval in the US in 2024. Contemporary real-world data on its effectiveness and safety remain limited. Objective To evaluate 30-day clinical, echocardiographic, and health status outcomes of TTVR in real-world use. Design, Setting, and Population Retrospective cohort study of all consecutive patients who underwent TTVR in the US from February 2024 through March 2025 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Patients had symptomatic, severe TR despite optimal medical therapy and TTVR was deemed appropriate by a heart team. Statistical analysis was conducted from September 2025 to February 2026. Exposure Device-enabled TTVR. Main Outcomes and Measures Thirty-day event rates (all-cause death, stroke, bleeding, new cardiac implantable electronic device [CIED] implantation, heart failure hospitalizations), TR reduction, and changes in health status (New York Heart Association [NYHA] functional class and Kansas City Cardiomyopathy Questionnaire Overall Summary [KCCQ-OS] score) are reported. Subgroup analyses examined the impact of baseline CIED status on outcomes. Results Among 1034 attempted procedures at 82 centers (mean [SD] age, 77.1 [10.6] years; 69.1% female; 73.2% NYHA functional class III/IV), a valve was successfully implanted in 1017 patients (98.4%). Mild or less TR was achieved in 98.4% of patients post procedure and in 97.7% at 30 days. At 30 days, all-cause mortality was 3.1%; stroke, 0.2%; bleeding, 7.9%; new CIED, 15.9% in CIED-naive patients; and heart failure hospitalization, 3.1%. There were significant improvements in NYHA functional class (class I/II, 82.7%; P < .001) and mean KCCQ-OS score (22.4 points; P < .001) from baseline to 30 days. There were no significant differences in 30-day mortality ( P = .47), heart failure hospitalization ( P > .99), and functional outcomes ( P = .55) when patients were stratified by baseline CIED status. Conclusions and Relevance Early US real-world experience with TTVR confirms safety and effectiveness in patients with severe TR. Thirty-day outcomes are consistent with the TRISCEND II pivotal trial, demonstrating acceptable safety, near-complete TR elimination, and significant health status improvements in an older, comorbid population. Rates of new CIED implantation and bleeding were lower than randomized clinical trial experience.
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Lurz, Philipp , Hahn, Rebecca T. , Kodali, Susheel , Makkar, Raj , Sharma, Rahul , Davidson, Charles J. , O’Neill, Brian , Yadav, Pradeep , Zahr, Firas , Chadderdon, Scott , Eleid, Mackram F. , Smith, Robert L, Garcia, Santiago , Kister, Tobias , Kipperman, Robert, Lim, Scott, Hermiller, James, Mishell, Jacob M. , Rassi, Andrew N., Szeto, Wilson Y. , Babaliaros, Vasilis , Barker, Colin M. , Summers, Matthew , Chetcuti, Stanley, Ailawadi, Gorav , Russo, Mark, Rinaldi, Michael, Chehab, Bassem , Nickenig, Georg, Stinis, Curtiss, Inglessis‐Azuaje, Ignacio , Dhoble, Abhijeet , Petrossian, George , Shah, Pinak, Staniloae, Cezar , Nores, Marcos, Singh, Gagan D. , Baldus, Stephan , Rudolph, Volker , Barb, Ilie, Klodell, C.T., Gray, William A. , Strote, Justin A, Sannino, Anna , Grayburn, Paul , Mack, Michael J. , Leon, Martin B. , Thourani, Vinod H. , Lim, D. Scott , Szerlip, Molly , Kister, Tobias , Lim, D Scott , Saxon, John , Kapadia, Samir , Mishell, Jacob M , Herrmann, Howard C , Hausleiter, Jörg , Babaliaros, Vasilis , Barker, Colin M , Lindman, Brian R , Latib, Azeem , von Bardeleben, Ralph Stephan , Summers, Matthew , Ailawadi, Gorav , Rinaldi, Michael , Chehab, Bassem M , Nickenig, Georg , Inglessis-Azuaje, Ignacio , Dhoble, Abhijeet , Chhatriwalla, Adnan K , Petrossian, George , Shah, Pinak , Staniloae, Cezar , Williams, Mathew , McCabe, James M , Singh, Gagan , Baldus, Stephan , Rudolph, Volker , Klodell, Charles , Gray, William , Strote, Justin , Sannino, Anna , Grayburn, Paul , Mack, Michael J , Thourani, Vinod H , Davidson, Charles J. , Hahn, Rebecca T , Lurz, Philipp , Smith, Robert L, Whisenant, Brian K. , Kapadia, Samir , Hausleiter, Jörg , Lindman, Brian R. , Latib, Azeem , Muhammad, Kamran I. , Williams, Mathew

Mayo Clinic

European Heart Journal | August 21, 2025 | Volume: 47 | Issue: 17 | Pages: 2059-2073

10.1093/eurheartj/ehaf676 | PMID 40878717 Get It

Abstract Background and Aims The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.